Follow-up study of expression of Bcl-2, Bax, p53 and ACE in CD34+ cells of peripheral blood and bone marrow in acute leukemia patients in the course of induction chemotherapy

Terapevticheskii Arkhiv

Volumn 83, Issue 7, 2011, Pages 32-37

  Khodunova, E E ^a   Parovichnikova, E N ^a   Galtseva, I V ^a   Kulikov, S M ^a   Isaev, V G ^a   Savchenko, V G ^a  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

53 and ACE; Acute leukemia; Apoptosis; Bax; Expression of Bcl 2

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CD34 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW; CASE CONTROL STUDY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; LEUKEMIA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE MARROW; CASE-CONTROL STUDIES; FLOW CYTOMETRY; HUMANS; LEUKEMIA; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 80052082877     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Testa U., Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007;92(1):81-94. (Pubitemid 46237556)
2. Li J., Volkov L. et al. Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp. Hematol. 1997;25:140-146. (Pubitemid 27101328)
3. Poeta G. D., Venditti A. et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003;101(6):2125-2131. (Pubitemid 36302046)
4. Marcucci G., Stock W. et al. Phase F study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 2005;23(15):3404-3411.
5. Aksu S., Beyazit Y. et al. Over-expression of angiotensin-converting enzyme (CD143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leukemia and Lymphoma 2006;47(5):891-896. (Pubitemid 43840646)
6. Cavalcanti G. B. Jr., Da Cunha Vasconcelos F., Pinto de Faria G. et al. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia. Cytometry B: Clin. Cytom. 2004;61(1):1-8. (Pubitemid 39223364)
7. Antonsson B., Martinou J. C. The Bcl-2 protein family. Exp. Cell Res. 2000;256(1):50-57. (Pubitemid 30211166)
8. Campos L., Rouault J. P., Sabido O. et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-3096. (Pubitemid 23162130)
9. Levine J. L. et al. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
10. Ladich H. et al. Molecular cell biology. Scientific American books. New Jork, 1995.
11. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-1449.
12. Kaufmann S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989;49:5870-5878. (Pubitemid 19274139)
13. - blast compartments in apoptosis resistance in acute myeloid leukemia. Hematological 2003;88:497-508. (Pubitemid 36648439)
14. Seliger B., Papadileris S., Vogel D. et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur. J. Hematol. 1996;57:230-240. (Pubitemid 26346036)
15. Gump J., McGavran L., Wei Q., Hunger S. P. Analysis of TP53 mutations in relapsed childhood acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 2001;23:416-425.
16. Jokubaitis V., Sinka L. et al. Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 2008;111:4055-4063.
17. Inigo S. D., Lopez-Jorge C. E., Gomez-Casares M. T. et al. Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents. Leukemia Res. 2009;33:810-816.
18. Beyazit Y, Aksu S., Haznedaroglu I. C. et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J. Natl Med. Assoc. 2007;99:57-63. (Pubitemid 46183959)
19. Herr I., Debatin K. M. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98(9):2603-2614.
20. Konopleva M., Tari A. M. et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000;95:3929-3938. (Pubitemid 30412870)
21. Haznedaroglu I. C, Beyazit Y. Pathobiological aspects of the local bone marrow renin-angiotensin system: a review. Renin-Angiotensin-Aldosterone Syst. 2010;11(4):205-213.
22. Aksu S., Beyazit Y., Haznedaroglu I. C. et al. Enhanced expression of the local haematopoietic bone marrow renin-angiotensin system in polycythemia Rubra vera. J. Int. Med. Res. 2005;33:661-667. (Pubitemid 43009593)
23. Srinivas G., Nair N. K., Panicker K. R., Pillai M. R. Mutant p53, Bcl-2/Bax ratios and apoptosis in pediatric acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 2000;126:62-67. (Pubitemid 30006354)
24. Hadir A., Nayera H. et al. The expression of Bcl-2 and Bax Proteins and their clinical relevance in ALL and CLL patients. J. Egypt. Natl. Cancer Inst. 2001;13(1):35-42.